Clinical Efficacy of Nasal High-Flow Humidified Oxygen Therapy in Patients with Chronic Obstructive Pulmonary Disease Complicated by Type Ⅱ Respiratory Failure
Objective To explore the clinical efficacy of nasal high-flow humidified oxygen therapy in the treatment of chronic obstructive pulmonary disease(COPD)complicated by Type Ⅱ respiratory failure.Methods A total of 84 patients diagnosed with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)and Type Ⅱ respiratory failure,treated at Nanyang Central Hospital from January 2021 to December 2023,were selected as study subjects.Patients were randomly divided into two groups,with 42 patients in each group.The control group received non-invasive positive pressure ventilation,while the observation group received nasal high-flow humidified oxygen therapy.The two groups were compared before and after treatment regarding arterial blood oxygen partial pressure(PaO2),arterial carbon dioxide partial pressure(PaCO2),pH value,mean arterial pressure(MAP),heart rate,respiratory rate,C-reactive protein,interleukin-6(IL-6),tumor necrosis factor-alpha(TNF-α),quality of life[St.George's Respiratory Questionnaire(SGRQ)],and comfort level[Kolcaba Comfort Questionnaire(GCQ)].The length of hospital stay and the occurrence of adverse reactions were also recorded for both groups.Results Before treatment,there were no statistically significant differences in PaO2,PaCO2,pH value,MAP,heart rate,and respiratory rate between the two groups(P＞0.05).After treatment,both groups showed increased PaO2 and pH values,and decreased PaCO2,MAP,heart rate,and respiratory rate,with the observation group exhibiting significantly lower heart rate and respiratory rate compared to the control group(P＜0.05).However,there were no significant differences in PaO2,PaCO2,pH value,and MAP between the two groups post-treatment(P＞0.05).Prior to treatment,C-reactive protein,IL-6,and TNF-α levels showed no significant differences between the groups(P＞0.05).After treatment,both groups had significantly lower levels of C-reactive protein,IL-6,and TNF-α,with the observation group being lower than the control group the difference was statistically significant(P＜0.05).Before treatment,SGRQ and GCQ scores showed no significant differences(P＞0.05).After treatment,both groups had decreased SGRQ scores and increased GCQ scores,with the observation group showing lower SGRQ scores and higher GCQ scores compared to the control group the difference was statistically significant(P＜0.05).The length of hospital stay and the incidence of adverse reactions were lower in the observation group than in the control group the difference was statistically significant(P＜0.05).Conclusion Both nasal high-flow humidified oxygen therapy and non-invasive positive pressure ventilation are effective treatments for acute exacerbation of COPD with Type Ⅱ respiratory failure.However,nasal high-flow humidified oxygen therapy demonstrates better outcomes in alleviating symptoms,reducing inflammatory responses,and enhancing comfort and patient tolerance,ultimately improving the quality of life and reducing the occurrence of adverse events.
国家科技期刊平台
NSTL
万方数据
